Products
Ocankitug Biosimilar Monoclonal Antibody (TSLP) for Research
Cat No.: GMP-Bios-INN-1308
Anti-TSLP therapeutic antibody (Pre-made Ocankitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ocankitug (development code CM-326) is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP). It is developed by CSPC Pharmaceutical Group and KeyMed Biosciences for asthma, atopic dermatitis, and COPD. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1308-1mg | 1mg | 3090 |
| GMP-Bios-INN-1308-10mg | 10mg | |
| GMP-Bios-INN-1308-100mg | 100mg | |
| GMP-Bios-INN-1308-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ocankitug biosimilar, Whole mAb, Anti-TSLP Antibody: Anti-TSLP/Thymic stromal lymphopoietin therapeutic antibody |
| INN Name | Ocankitug |
| Target | TSLP |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | CSPC Pharmaceutical Group;KeyMed Biosciences |
| Conditions Approved | na |
| Conditions Active | Asthma;Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
